http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 13 May 2026 17:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Armata+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Innoviva%2C+Inc./26487613.html si-local-file:///var/storage/secattach/20260513/26487613.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Armata+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Innoviva%2C+Inc./26487613.html Wed, 13 May 2026 17:22:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Armata+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Innoviva%2C+Inc./26487613.html si-local-file:///var/storage/secattach/20260513/26487613.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Armata+Pharmaceuticals%2C++++++++++++++++Filed+by%3A+Innoviva%2C+Inc./26487613.html Wed, 13 May 2026 17:22:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Armata+Pharmaceuticals%2C+++For%3A+Mar+31/26487112.html si-local-file:///var/storage/secattach/20260513/26487112.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Armata+Pharmaceuticals%2C+++For%3A+Mar+31/26487112.html Wed, 13 May 2026 16:50:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Armata+Pharmaceuticals%2C+++For%3A+Mar+31/26487112.html si-local-file:///var/storage/secattach/20260513/26487112.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Armata+Pharmaceuticals%2C+++For%3A+Mar+31/26487112.html Wed, 13 May 2026 16:50:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+May+12/26486828.html si-local-file:///var/storage/secattach/20260513/26486828.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+May+12/26486828.html Wed, 13 May 2026 16:34:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+May+12/26486828.html si-local-file:///var/storage/secattach/20260513/26486828.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+May+12/26486828.html Wed, 13 May 2026 16:34:00 -0400 ARMP O.00168871 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html <div class="xn-content"> <p class="prntac"><i>Entered into secured credit agreement with Innoviva for <money>$25 million</money> maturing in 2029</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>May 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended <chron>March 31, 2026</chron>, and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Announces+First+Quarter+2026+Results+and+Provides+Corporate+Update/26486689.html Wed, 13 May 2026 16:30:00 -0400 A.06822034 A.10662136 A.19655944 A.27822871 A.38032151 A.50208593 A.50216777 ARMP O.00168871 O.00303771 O.00366519 O.03307993 O.04698756 O.20026344 O.36397598 O.54516537